These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15257935)

  • 1. Extramedullary multiple myeloma escapes the effect of thalidomide.
    Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
    Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide in refractory and relapsing multiple myeloma.
    Bladé J; Esteve J; Rosiñol L; Perales M; Montoto S; Tuset M; Montserrat E
    Semin Oncol; 2001 Dec; 28(6):588-92. PubMed ID: 11740814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
    Cibeira MT; Rosiñol L; Ramiro L; Esteve J; Torrebadell M; Bladé J
    Eur J Haematol; 2006 Dec; 77(6):486-92. PubMed ID: 16978238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
    Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E
    Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
    N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide treatment of resistant or relapsed multiple myeloma patients.
    Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J;
    Haematologica; 2001 Apr; 86(4):404-8. PubMed ID: 11325647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
    Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
    Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
    Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A
    Haematologica; 2004 May; 89(5):552-6. PubMed ID: 15136218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
    Wasser K; Moehler T; Neben K; Nosas S; Heiss J; Goldschmidt H; Hillengass J; Düber C; Kauczor HU; Delorme S
    Rofo; 2004 Sep; 176(9):1285-95. PubMed ID: 15346264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
    Radocha J; Maisnar V
    Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
    Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma].
    Kyrcz-Krzemień S; Helbig G; Stella-Hołowiecka B; Hołowiecki J
    Wiad Lek; 2003; 56(5-6):227-32. PubMed ID: 14526479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.
    Corso A; Zappasodi P; Barbarano L; Petrucci MT; Palumbo A; Caravita T; Mangiacavalli S; Cafro AM; Varettoni M; Gay F; Morra E; Lazzarino M
    Leuk Res; 2009 Sep; 33(9):e145-9. PubMed ID: 19375164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
    Wang M; Liu Y; Li Y; Wu H
    Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
    Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
    Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.